Search
Abacavir
go.drugbank.com/drugs/DB01048ApprovedInvestigationalIn vivo, abacavir sulfate dissociates to its free base, abacavir. … Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring.
Synonyms: {(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanolMixtures: N/AAnagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnAzficel-T is marketed in the US as Laviv for intradermal injection. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.
Padeliporfin
go.drugbank.com/drugs/DB15575ApprovedInvestigational[A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799] … Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies.
Categories: Sensitizers Used in Photodynamic/radiation Therapy, Heterocyclic Compounds with 4 or More RingsSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigational[L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR … The antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation
Hetacillin
go.drugbank.com/drugs/DB00739ApprovedVet approvedWithdrawnHetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin. … The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseLiothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approvedLiothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. … Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3.
Mixtures: Np Thyroid 90, NP Thyroid 30Categories: Agents used to treat hypothyroidismAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[L2931] It is administered orally as the salt form avatrombopag maleate. … [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure.
Darunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigational[L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection. … [L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006.
Synonyms: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate, (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamateMixtures: VIRONTAR N COMPRIMIDOS RECUBIERTOS, VIRONTAR N COMPRIMIDOS RECUBIERTOSElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. … [L44918,L44948] It received a similar approval in the EU in September 2023.
Categories: Estrogens, Non-Steroidal